'Most feared' activist investor in America has zeroed in on Bristol-Myers Squibb. Is he planning to derail the $74B Celgene buyout?
The “most feared man in corporate America” has just set his sights on Bristol-Myers Squibb. And that may make some of Bristol-Myers more than a little uncomfortable this morning as they continue to push their controversial $74 billion Celgene buyout.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.